Which statement best reflects osteoporosis management for a patient with a vertebral fracture?

• A. Pharmacotherapy should be considered based on fracture history even if T-score is not in osteoporosis range
• B. Pharmacotherapy should be deferred until T-score reaches -2.5
• C. Fractures do not influence treatment decisions
• D. Vitamin D alone is sufficient for all patients

Answer: (A)

Prior vertebral fracture indicates very high fracture risk, so treatment decisions focus on the clinical history of fracture as a key driver, not solely on bone density. When a vertebral fracture is present, starting osteoporosis pharmacotherapy is appropriate even if the T-score hasn’t reached osteoporosis range. Medications that slow bone loss or build bone have been shown to reduce the risk of subsequent fractures, addressing a risk that density measurements alone can miss.

Deferring therapy until the T-score reaches -2.5 ignores the strong risk signal from a prior fracture and misses an opportunity to prevent another fracture. The idea that fractures don’t influence treatment decisions is incorrect because a previous fracture is one of the strongest predictors of future fractures. And relying on Vitamin D alone isn’t sufficient for most patients with osteoporosis and fracture risk, since medications that modify bone turnover are typically needed to meaningfully reduce fracture risk while ensuring adequate vitamin D and calcium.